Selected Hypoxic Stop-flow Perfusions: Indication and Limits

Aims and Background The treatment of unresectable cancers is still one of the main medical challenges. Stop-flow perfusion has been used as locoregional chemotherapy based on blood supply blockage of the tumor-bearing area. The aim of the present paper is to report our personal experience in the clinical use of hypoxic stop-flow perfusion and discuss future prospects for research. Methods and Study Design Since December 1997 more than 500 stop-flow perfusions have been performed at the University of L'Aquila. Hypoxic perfusion was adopted for the following indications: recurrent rectal cancer, advanced pancreatic cancer, recurrent pelvic and limb melanoma, and recurrent limb melanoma. Results For recurrent rectal cancer median survival was 12.2 months, for advanced pancreatic cancer 9.6 months, for recurrent pelvic and limb melanoma 34.4 months, and for recurrent limb melanoma 23.8 months. Conclusions Based on these encouraging results, stop-flow perfusion should be considered an effective treatment. Future fields of research include tailored chemotherapy and hyperthermia.

[1]  M. Valenti,et al.  Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study , 2003, Melanoma research.

[2]  M. Valenti,et al.  Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. , 2002, American journal of surgery.

[3]  M. Valenti,et al.  Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer. , 2001, Archives of surgery.

[4]  S. Guadagni.  Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  K. Aigner,et al.  Pharmacokinetics of Mitomycin C in Pelvic Stopflow Infusion and Hypoxic Pelvic Perfusion with and without Hemofiltration: A Pilot Study of Patients with Recurrent Unresectable Rectal Cancer , 1998, Journal of clinical pharmacology.

[6]  P. Kam,et al.  A percutaneous aortic stop-flow infusion technique for regional cytotoxic therapy of the abdomen and pelvis , 1994 .

[7]  K. Aigner,et al.  Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer , 1994 .

[8]  A. Wile,et al.  Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer. , 1987, Archives of surgery.

[9]  E. Watkins,et al.  The use of intravascular balloon catheters for isolation of the pelvic vascular bed during pump-oxygenator perfusion of cancer chemotherapeutic agents. , 1960, Surgery, gynecology & obstetrics.

[10]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.